Deals in brief
OSE Immunotherapeutics and MAbSilico enter AI partnership
Codagenix partners Serum Institute of India on Covid-19 vaccine
Biotechnology firm Codagenix has partnered with vaccine manufacturer Serum Institute of India to work together for the development of a vaccine for the new coronavirus.
The partners intend to develop a live-attenuated vaccine, which can induce an immune response to different antigens of the virus and enables scale for mass production, among other benefits.
Dr Reddy’s to buy some Wockhardt generics units for $259m
Bayer to transfer research unit in Berlin to Nuvisan
Healthcare company Bayer has signed a definitive agreement to transfer the majority of its small molecule research unit in Berlin, Germany to Nuvisan.
Nuvisan provides clinical, laboratory and contract manufacturing services. The company has six sites in Germany and France, along with monitoring operations in the US, Argentina, Brazil and Peru.
The research unit in Berlin has an operational team for small molecule research.
Under the agreement, Bayer will retain certain research activities in Berlin, the headquarters for its Pharmaceuticals division.
J&J partners HHS to speed-up coronavirus vaccine development
Luye Pharma grants certain rights for Seroquel to Cipla Medpro
Assertio to divest US rights to Nucynta to Collegium for $375m
Assertio Therapeutics has signed a definitive agreement to sell its Nucynta franchise to Collegium Pharmaceutical for a cash consideration of $375m.
The deal will provide Collegium with the US licence for the Nucynta franchise of products. Besides $375m, Collegium will pay Assertio for some inventories and equipment related to the products.
Under the agreement, Collegium will be exempt from paying royalties to Assertio.